{"denoms":[{"counts":[{"groupId":"BG000","value":"425"}],"units":"Participants"}],"groups":[{"description":"Patients received 6 or 8 21-day cycles of CHOP (cyclophosphamide, hydroxydaunorubicin \\[doxorubicin\\], Oncovin \\[vincristine\\], prednisone) or CVP (cyclophosphamide, vincristine, prednisone) in combination with rituximab 375 mg/m\\^2 administered by intravenous (IV) infusion on Day 1 of each cycle.","id":"BG000","title":"Rituximab 375 mg/m^2"}],"measures":[{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","spread":"13.4","value":"62.7"}]}]}],"description":"Demographic data are reported for the intent-to-treat (ITT) population which included all patients who received at least 1 dose of rituximab regardless of infusion rate. Of the 451 enrolled patients, 26 withdrew before receiving treatment and were not included in the ITT population.","dispersionType":"STANDARD_DEVIATION","paramType":"MEAN","title":"Age, Continuous","unitOfMeasure":"years"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"191"}],"title":"Female"},{"measurements":[{"groupId":"BG000","value":"234"}],"title":"Male"}]}],"description":"Demographic data are reported for the intent-to-treat (ITT) population which included all patients who received at least 1 dose of rituximab regardless of infusion rate. Of the 451 enrolled patients, 26 withdrew before receiving treatment and were not included in the ITT population.","paramType":"COUNT_OF_PARTICIPANTS","title":"Sex: Female, Male","unitOfMeasure":"Participants"}]}